Transformational technologies
for therapeutic breakthroughs.
We'll take your molecule to IND in reduced time, with reduced costs & reduced risk.
We believe in the power of imagination. And of collaboration.
We partner with therapeutic developers to accelerate their drug discovery program and make it more efficient, secure and certain.
Expert scientists with extraordinary ides. Transforming them into pathbreaking technologies.
150 People strong
Prabuddha Kundu is a cofounder and Managing Director at Premas Biotech. He has 20 years of experience in various roles and capacities. He holds a Ph.D. in Biomedical Engineering from Indian Institute of Technology, Mumbai, and has interests in protein engineering, bioprocess development, lean transformation, and new technologies. He has more than 22 publications and 10 patents.
Nupur is a co-founder & the Chief Operating Officer at Premas and responsible for global operations leading key client projects. She has 23 years experience as a clinician, a researcher and an operations head. Her main research interest is infectious diseases. She is a co-inventor on 6 patent applications.
Avijit is an entrepreneur with several business start ups and turnarounds to his credit . He has been a leader in “management of change” thinking and application . He has three decades of leadership, management & business experience across Africa, Middle East and Asia . He is extremely passionate about creating work cultures that excel in innovation, ownership and performance.
Premas specializes in developing
recombinant proteins for vaccine
development. Such proteins are often
“difficult to express proteins” (DTE-Ps).
Our innovative D-Crypt platform is
optimized for highyield production of
DTE-Ps, singularly, or in combination.
Through a partnership with Akers
Biosciences, Premas is leveraging DCrypt to develop a multicomponent
recombinant protein vaccine against
COVID-19.